查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1993153

生物活性玻璃市場：2026-2032年全球市場預測（按產品類型、形態、分銷管道、應用和最終用戶分類）

Bioactive Glass Market by Product Type, Form, Distribution Channel, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，生物活性玻璃市場價值將達到 288.9 億美元，到 2026 年將成長至 313.6 億美元，到 2032 年將達到 509 億美元，複合年成長率為 8.42%。

主要市場統計數據
基準年 2025 288.9億美元
預計年份：2026年 313.6億美元
預測年份 2032 509億美元
複合年成長率 (%) 8.42%

全面介紹生物活性玻璃技術。本次演講將概述其臨床意義、材料發展歷程以及在醫學應用中的轉化價值。

生物活性玻璃從突破性的實驗室發現發展成為多個臨床和研究領域的核心材料。最初，人們開發生物活性玻璃是因為它具有與骨骼和軟組織結合的獨特能力。如今，現代的成分和加工技術已將其應用擴展到牙科修復材料、藥物遞送基質、整形外科植入和人工組織支架等領域。溶膠-凝膠化學、離子交換和表面功能化技術的進步，使得人們能夠製造出不僅支持結構修復，還能主動調節細胞反應和局部微環境的材料。

材料創新、臨床需求和不斷變化的法規如何改變生物活性玻璃領域的產品開發和商業化路徑？

近年來，科學、臨床和商業性因素的共同作用，推動了生物活性玻璃領域的變革性發展。在科學方面，玻璃化學和積層製造技術的進步使得客製化結構成為可能，這些結構具有可控的孔隙率和離子發射分佈，從而實現了更可重複的生物反應。同時，表面塗層和複合材料整合技術的改進提高了植入的耐久性和生物相容性，減少了發炎反應，促進了骨整合。

本研究評估了 2025 年關稅政策趨勢將如何重塑整個生物活性玻璃價值鏈的供應鏈策略、製造地和定價槓桿。

近期政策週期中關稅的徵收和提高對生物活性玻璃價值鏈上的企業產生了複雜的營運和戰略影響。關稅改變了進口原料（例如矽和鈣源）、溶膠-凝膠加工中使用的特殊試劑以及跨境供應的成品組件的成本基礎。對於依賴一體化全球供應鏈的製造商而言，這些成本波動迫使他們重新評估籌資策略、庫存政策和跨境轉移定價。

將臨床應用、成分選擇、產品形式、最終用戶偏好和通路與商業性成果聯繫起來的綜合細分分析。

細分市場洞察揭示了臨床需求與產品創新和分銷動態的交匯點，突顯了技術開發和商業性重點的集中領域。從應用角度來看，牙科領域涵蓋根管治療和牙周治療，旨在滿足牙齒結構內外的再生需求。在藥物遞送領域，生物活性玻璃被用作抗菌劑和生長因子的緩釋基質。整形外科領域專注於骨再生和脊椎融合手術，其中支架結構和離子釋放至關重要。此外，組織工程涵蓋骨骼、軟骨和血管組織，每種組織都需要獨特的機械性能和生物功能特性。

美洲、歐洲、中東和非洲以及亞太地區的趨勢和實施模式存在區域差異，這些差異影響監管策略和市場發展。

區域趨勢對生物活性玻璃各項應用的技術採納、監管成熟度和供應鏈策略的形成至關重要。在美洲，臨床體系和報銷環境強烈支持實證實踐，牙科領域的創新和整形外科植入的研發也十分活躍。此外，具備生產能力的一體化牙科供應鏈支援快速商業化和臨床醫生培訓計畫。歐洲、中東和非洲地區的情況則較為複雜。部分歐洲市場的監管協調與其它地區的多樣化准入和採購機制形成鮮明對比，導致集中核准和區域採納策略並存，這些策略都強調成本效益和臨床療效。

決定生物活性玻璃製造商競爭差異化、擴充性和臨床檢驗軌蹟的企業策略和合作方式。

生物活性玻璃生態系中的公司層級行動因其規模、技術傳承和市場重點的不同，展現出不同的策略立場。跨國材料製造商投資於模組化生產線和跨境監管合規團隊，以適應各種不同的成分和形狀，而小規模的專業公司則專注於小眾臨床適應症、高價值牙科耗材或獨特的支架結構。Start-Ups和大學衍生企業往往是顛覆性創新的驅動力，尤其是在積層製造和生物複合材料領域，但它們通常與現有經銷商和聯合開發夥伴合作，以獲得臨床管道並擴大生產規模。

針對產品、監管、供應鏈和商業策略提出切實可行的優先建議，以加速臨床部署和提高組織韌性。

產業領導者應將研發重點與清晰的臨床價值提案和實證實踐相結合，以加速產品推廣應用。他們應投資於平台技術，實現產品系列成分的調整，從而能夠從單一生產基地提供適用於不同適應症的塗層、粉末、糊劑和支架。在材料研發的同時，也應制定系統性的轉化證據產生計劃，包括嚴格的臨床前終點指標、盡可能進行多中心臨床試驗，以及收集真實世界數據以證明功能性結果和治療效果。

採用混合方法研究框架，結合專家訪談、文獻整合和情境分析，以確保技術、臨床和商業性發現的檢驗。

本調查方法旨在透過結合定性專業知識和系統性的證據整合，得出可靠且可操作的結論。主要研究包括對牙科和整形外科醫生、醫院和診所採購經理、材料和醫療設備製造商的技術總監以及監管專家進行結構化訪談。這些訪談深入探討了影響產品採納決策的最重要因素：治療偏好、操作特性和臨床終點。次要研究包括對同行評審文獻、監管指導文件、臨床試驗註冊資訊和公開技術標準進行主題回顧，以全面檢驗性能聲明和安全性考慮。

一份權威的綜合分析報告，重點闡述了產品、證據和供應策略的協調將如何決定生物活性玻璃技術的未來發展和臨床影響。

總之，生物活性玻璃正處於一個轉折點，成熟的材料科學、細緻的臨床需求以及不斷發展的商業環境正為其更廣泛的應用鋪平道路。這項技術的核心優勢——生物活性、可調控的溶解度以及釋放功能性離子的能力——與牙科修復、整形外科再生和人工組織等領域的臨床目標高度契合。然而，要最大限度地發揮這些材料的潛力，需要在產品設計、臨床證據產生和供應鏈策略等方面進行協調努力。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：生物活性玻璃市場：依產品類型分類

  • 13-93
  • 45S5
  • 58S
  • S53P4

第9章：生物活性玻璃市場：依形態分類

  • 塗層
  • 粉末
  • 油灰
  • 鷹架

第10章：生物活性玻璃市場：依通路分類

  • 直銷
  • 銷售代理

第11章：生物活性玻璃市場：依應用領域分類

  • 牙科
    • 根管治療用途
    • 牙周治療
  • 藥物輸送
  • 整形外科
    • 骨再生
    • 脊椎融合手術
  • 組織工程
    • 骨組織
    • 軟骨組織
    • 血管組織

第12章：生物活性玻璃市場：依最終用戶分類

  • 牙醫診所
  • 醫院
  • 研究機構

第13章：生物活性玻璃市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：生物活性玻璃市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：生物活性玻璃市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國生物活性玻璃市場

第17章：中國生物活性玻璃市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • 3M Company
  • AGC Inc.
  • Baxter International Inc.
  • BioGlass SRL
  • Biomin GmbH
  • Bonalive Biomaterials Ltd
  • CoorsTek, Inc.
  • Curasan, Inc.
  • Dentsply Sirona
  • Elos Medtech AB
  • Ferro Corporation
  • Johnson & Johnson
  • LASAK sro
  • Matexcel
  • Mo-Sci Corporation
  • NanoFUSE Biologics LLC
  • NORAKER
  • NovaBone Products, LLC
  • Orthovita, Inc.
  • Perimed AB
  • SCHOTT AG
  • Shanghai Bio-lu Biomaterials Co., Ltd.
  • Sinoss GmbH
  • Stryker Corporation
  • Synergy Biomedical, LLC
  • Vetra Biomaterials
  • Vitrostech
  • Zimmer Biomet Holdings, Inc.
Product Code: MRR-1A1A064C02E5

The Bioactive Glass Market was valued at USD 28.89 billion in 2025 and is projected to grow to USD 31.36 billion in 2026, with a CAGR of 8.42%, reaching USD 50.90 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 28.89 billion
Estimated Year [2026] USD 31.36 billion
Forecast Year [2032] USD 50.90 billion
CAGR (%) 8.42%

A comprehensive contextual introduction to bioactive glass technology outlining its clinical relevance, material evolution, and translational significance across healthcare applications

Bioactive glass has transitioned from a laboratory breakthrough to a cornerstone material across multiple clinical and research domains. Initially developed for its unique ability to bond with bone and soft tissues, modern compositions and processing techniques have expanded its utility into dental restoratives, drug delivery matrices, orthopedic implants, and engineered tissue scaffolds. Advances in sol-gel chemistry, ion substitution, and surface functionalization now enable materials that not only support structural repair but actively modulate cellular responses and local microenvironments.

This introduction frames the technology's relevance to clinicians, materials scientists, and commercial strategists. In clinical practice, bioactive glass applications span endodontic procedures and periodontal therapies in dentistry, while orthopedics leverages formulations for bone regeneration and fusion. In parallel, tissue engineering research exploits compositional tuning to promote osteogenesis, chondrogenesis, and vascularization. Coupled with varied product forms such as coatings, powders, putties, and scaffolds, these developments underpin a diversified supply chain from specialized manufacturers to hospital procurement.

As regulatory pathways evolve and translational pipelines accelerate, understanding the material science alongside clinical evidence and distribution dynamics becomes essential. This report synthesizes the technical foundations and application contexts to equip leaders with a clear orientation of where bioactive glass delivers differentiated clinical value and where further innovation is required to overcome adoption barriers.

How material innovation, clinical demand, and regulatory evolution are collectively reshaping product development and commercialization pathways in the bioactive glass sector

Recent years have witnessed transformative shifts across the bioactive glass landscape driven by converging scientific, clinical, and commercial forces. At the scientific front, precision in glass chemistry and additive manufacturing have enabled bespoke architectures with controlled porosity and ion release profiles, which in turn drive more reproducible biological responses. Parallel improvements in surface coatings and composite integration have expanded implant longevity and compatibility, reducing inflammatory responses and enhancing osseointegration.

Clinically, there is a discernible move from single-use, filler-type applications toward multifunctional constructs that combine structural repair with localized therapeutic delivery. This paradigm shift reflects broader healthcare priorities emphasizing minimally invasive procedures, faster recovery times, and lower infection risks. Commercially, strategic alliances between materials firms, dental suppliers, and implant manufacturers are reshaping route-to-market strategies, concentrating on bundled solutions that simplify clinician workflows and procurement.

Regulatory expectations and payer scrutiny are also evolving; device dossiers increasingly require robust preclinical models, histological endpoints, and translational biomarkers to substantiate clinical benefits. Consequently, organizations that align their R&D, regulatory, and clinical evidence-generation strategies are better positioned to navigate reimbursement landscapes and accelerate adoption. Taken together, these shifts indicate a maturing field where incremental material advances are being translated into systemic changes in how therapies are designed, delivered, and valued.

Assessing how tariff policy dynamics in 2025 have reoriented supply chain strategies, manufacturing footprints, and pricing levers across the bioactive glass value chain

The imposition and escalation of tariffs in recent policy cycles have introduced a complex set of operational and strategic impacts for companies engaged in the bioactive glass value chain. Tariffs alter the cost basis for imported raw precursors such as silicon and calcium sources, specialized reagents used in sol-gel processing, and finished components supplied across borders. For manufacturers relying on integrated global supply chains, these cost shifts necessitate reassessment of sourcing strategies, inventory policies, and cross-border transfer pricing.

Beyond direct cost effects, tariffs influence competitive positioning. Organizations with localized manufacturing footprints or vertical integration can internalize fewer external cost shocks, creating relative advantages in margin stability and price competitiveness. Conversely, firms dependent on third-party suppliers or contract manufacturers in tariff-affected jurisdictions face margin compression or must accept lead-time variability as procurement shifts to alternative suppliers.

Operationally, some companies respond by redesigning bills of materials to reduce tariff exposure, substituting components where clinically and regulatory feasible, or increasing emphasis on domestic supply relationships. Others accelerate investments in automation and process efficiency to offset rising input costs without compromising clinical specifications. Importantly, tariffs also amplify the strategic value of distribution choices: direct sales channels enable tighter margin control and dynamic pricing, whereas reliance on distributors can diffuse tariff-related costs across broader networks but may conceal incremental pricing pressures from end-users. Overall, the tariff environment in 2025 has elevated supply chain resilience and manufacturing localization from tactical priorities to central pillars of corporate strategy.

Integrated segmentation analysis connecting clinical applications, compositional choices, product forms, end-user preferences, and distribution pathways to commercial outcomes

Segmentation insights reveal where clinical demand intersects with product innovation and distribution dynamics, highlighting areas of concentrated technical development and commercial focus. When viewed through the lens of application, dentistry encompasses both endodontic applications and periodontal treatment, addressing regenerative needs inside and around the tooth structure; drug delivery leverages bioactive glass as a controlled-release matrix for antimicrobials and growth factors; orthopedics is oriented toward bone regeneration and spinal fusion procedures where scaffold architecture and ion release are paramount; and tissue engineering spans bone tissue, cartilage tissue, and vascular tissue, each demanding distinct mechanical and biofunctional profiles.

Examining product type sheds light on compositional preferences and performance trade-offs. Classic formulations such as 13-93 and 45S5 remain reference points for bioactivity and dissolution behavior, while variants like 58S and S53P4 are selected for specific angiogenic or antimicrobial attributes. Form factor decisions-coating, powder, putty, and scaffold-reflect clinical workflows and handling requirements; coatings are optimized for implant surfaces, powders and putties for defect filling and minimally invasive delivery, and scaffolds when structural support and cell infiltration are required. End users include dental clinics, hospitals, and research institutes, each placing different emphases on ease of use, regulatory branding, and evidence thresholds. Finally, distribution choices between direct sales and distributors influence market reach, pricing transparency, and the ability to offer integrated training or product bundling. Together, these segmentation dimensions map the technical design choices to real-world clinical adoption patterns and commercial pathways.

Regional dynamics and differential adoption patterns across the Americas, Europe Middle East & Africa, and Asia-Pacific shaping regulatory strategy and market deployment

Regional dynamics are pivotal in shaping technology adoption, regulatory maturity, and supply chain strategies across bioactive glass applications. In the Americas, clinical systems and reimbursement environments frequently favor evidence-driven adoption, with strong activity in dental innovation and orthopedic implant development; manufacturing capacity and consolidated dental supply channels support rapid commercialization and clinician training programs. Europe, the Middle East & Africa presents a heterogenous landscape where regulatory harmonization in some European markets contrasts with varied access and procurement mechanisms in other jurisdictions, driving a mix of centralized approvals and localized adoption strategies that emphasize cost-effectiveness and clinical outcomes.

Asia-Pacific markets are characterized by both fast-growing clinical demand and significant manufacturing capabilities. Several countries in the region are notable for rapid hospital infrastructure expansion and active research ecosystems that advance translational applications in tissue engineering and drug delivery. These regional differences influence decisions on where to locate pilot production, how to design clinical evidence packages, and the nature of partnerships with local distributors or clinical networks. Navigating the nuanced regulatory, reimbursement, and procurement realities across these regions is essential for firms seeking scalable international rollouts and for tailoring product portfolios to local clinical and cost constraints.

Corporate strategies and collaborative approaches that determine competitive differentiation, scalability, and clinical validation trajectories across bioactive glass producers

Company-level behaviors within the bioactive glass ecosystem demonstrate divergent strategic postures depending on scale, technical heritage, and market focus. Multinational materials manufacturers are investing in modular production lines and cross-border regulatory teams to support a range of compositions and form factors, while smaller specialized firms concentrate on niche clinical indications, high-value dental consumables, or proprietary scaffold architectures. Startups and university spinouts often drive disruptive technical innovations, particularly in additive manufacturing and biofunctionalization, but they frequently partner with established distributors or co-development partners to access clinical channels and scale manufacturing.

Across these organizational types, successful companies share several common practices: disciplined IP strategies that protect formulation specificity and processing know-how; early engagement with regulatory bodies to streamline approval pathways; and investment in post-market evidence collection to demonstrate long-term clinical benefits. Firms are also differentiating via service layers such as clinician training, procedural support, and bundled implant systems that reduce the complexity of adoption. Strategic M&A and licensing arrangements are occurring where larger players seek to internalize specialized capabilities, while collaborative consortia with hospitals and research institutes accelerate clinical validation. Overall, corporate insights point toward a balanced mix of technological depth, regulatory acumen, and commercialization partnerships as determinants of competitive advantage.

Practical and prioritized recommendations for product, regulatory, supply chain, and commercial strategies that accelerate clinical adoption and organizational resilience

Industry leaders should align R&D priorities with clear clinical value propositions and evidence pathways to accelerate adoption. Invest in platform technologies that allow compositional tuning across a family of products so that a single manufacturing backbone can deliver coatings, powders, putties, and scaffolds adapted to different indications. Parallel to material development, create a structured plan for generating translational evidence that includes rigorous preclinical endpoints, multicenter clinical studies where feasible, and real-world data collection to demonstrate functional outcomes and procedural efficiencies.

Operationally, diversify supply chain sources and examine regional manufacturing or toll-production options to reduce exposure to tariff volatility and logistics disruptions. Adopt modular production practices and quality systems that facilitate rapid validation of new compositions without extensive requalification. Commercially, tailor go-to-market models by region and end user: dental clinics often favor products that reduce chair time and simplify protocols, hospitals emphasize integrated implant systems with predictable inventory management, and research institutes seek open platforms that enable collaborative studies. Finally, cultivate strategic partnerships spanning distribution, clinical research, and complementary implant technologies to extend reach and share risk in evidence generation. Executing on these recommendations will improve resilience, accelerate clinical uptake, and create defensible differentiation in a competitive field.

A mixed-methods research framework combining expert interviews, literature synthesis, and scenario analysis to validate technical, clinical, and commercial insights reliably

The research methodology integrates qualitative expertise with systematic evidence synthesis to ensure robust, actionable conclusions. Primary research comprised structured interviews with clinicians across dentistry and orthopedics, procurement leaders from hospitals and clinics, technical leaders at materials and device firms, and regulatory specialists. These conversations provided insight into procedural preferences, handling characteristics, and clinical endpoints that matter most to adoption decisions. Secondary research involved thematic review of peer-reviewed literature, regulatory guidance documents, clinical trial registries, and publicly available technical standards to triangulate performance claims and safety considerations.

Analytical frameworks included segmentation mapping across applications, product types, form factors, end users, and distribution channels, enabling cross-sectional analysis of adoption barriers and commercial levers. Supply chain stress-testing scenarios were constructed to evaluate responses to cost shocks and tariff changes, emphasizing operational tactics such as localized production and BOM substitution. Data validation procedures combined cross-interview corroboration with document-level evidence, and findings were iteratively refined through expert review sessions. This mixed-method approach ensures that the report's insights reflect both lived clinical experience and the rigor of technical and regulatory documentation.

Conclusive synthesis highlighting how coordinated product, evidence, and supply strategies will determine the trajectory and clinical impact of bioactive glass technologies

In summary, bioactive glass stands at a juncture where matured material science, nuanced clinical needs, and evolving commercial structures are creating tangible pathways to broader adoption. The technology's core strengths-bioactivity, tunable dissolution, and capacity for functional ion release-align closely with clinical objectives in dental repair, orthopedic regeneration, and engineered tissues. However, realizing the full potential of these materials requires coordinated action across product design, clinical evidence generation, and supply chain strategy.

Leaders who prioritize modular product platforms, proactive regulatory engagement, and diversified manufacturing footprints will be better equipped to navigate policy-induced cost pressures and regional market complexities. Similarly, strategic partnerships that bundle technical capability with clinical training and distribution reach will reduce friction during clinician adoption. Ultimately, the trajectory of bioactive glass will be determined not only by laboratory innovation but by the capacity of organizations to translate material advantages into reproducible, cost-effective clinical outcomes that satisfy regulators, payers, and providers alike.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bioactive Glass Market, by Product Type

  • 8.1. 13-93
  • 8.2. 45S5
  • 8.3. 58S
  • 8.4. S53P4

9. Bioactive Glass Market, by Form

  • 9.1. Coating
  • 9.2. Powder
  • 9.3. Putty
  • 9.4. Scaffold

10. Bioactive Glass Market, by Distribution Channel

  • 10.1. Direct Sales
  • 10.2. Distributors

11. Bioactive Glass Market, by Application

  • 11.1. Dentistry
    • 11.1.1. Endodontic Applications
    • 11.1.2. Periodontal Treatment
  • 11.2. Drug Delivery
  • 11.3. Orthopedics
    • 11.3.1. Bone Regeneration
    • 11.3.2. Spinal Fusion
  • 11.4. Tissue Engineering
    • 11.4.1. Bone Tissue
    • 11.4.2. Cartilage Tissue
    • 11.4.3. Vascular Tissue

12. Bioactive Glass Market, by End User

  • 12.1. Dental Clinics
  • 12.2. Hospitals
  • 12.3. Research Institutes

13. Bioactive Glass Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Bioactive Glass Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Bioactive Glass Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Bioactive Glass Market

17. China Bioactive Glass Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. 3M Company
  • 18.6. AGC Inc.
  • 18.7. Baxter International Inc.
  • 18.8. BioGlass S.R.L.
  • 18.9. Biomin GmbH
  • 18.10. Bonalive Biomaterials Ltd
  • 18.11. CoorsTek, Inc.
  • 18.12. Curasan, Inc.
  • 18.13. Dentsply Sirona
  • 18.14. Elos Medtech AB
  • 18.15. Ferro Corporation
  • 18.16. Johnson & Johnson
  • 18.17. LASAK s.r.o.
  • 18.18. Matexcel
  • 18.19. Mo-Sci Corporation
  • 18.20. NanoFUSE Biologics LLC
  • 18.21. NORAKER
  • 18.22. NovaBone Products, LLC
  • 18.23. Orthovita, Inc.
  • 18.24. Perimed AB
  • 18.25. SCHOTT AG
  • 18.26. Shanghai Bio-lu Biomaterials Co., Ltd.
  • 18.27. Sinoss GmbH
  • 18.28. Stryker Corporation
  • 18.29. Synergy Biomedical, LLC
  • 18.30. Vetra Biomaterials
  • 18.31. Vitrostech
  • 18.32. Zimmer Biomet Holdings, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOACTIVE GLASS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOACTIVE GLASS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIOACTIVE GLASS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BIOACTIVE GLASS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BIOACTIVE GLASS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIOACTIVE GLASS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY 13-93, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY 13-93, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY 13-93, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY 45S5, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY 45S5, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY 45S5, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY 58S, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY 58S, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY 58S, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY S53P4, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY S53P4, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY S53P4, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY COATING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY COATING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY COATING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY PUTTY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY PUTTY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY PUTTY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY SCAFFOLD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY SCAFFOLD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY SCAFFOLD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY DENTISTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY DENTISTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY DENTISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY DENTISTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY ENDODONTIC APPLICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY ENDODONTIC APPLICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY ENDODONTIC APPLICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY PERIODONTAL TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY PERIODONTAL TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY PERIODONTAL TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY DRUG DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY DRUG DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY DRUG DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY ORTHOPEDICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY ORTHOPEDICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY ORTHOPEDICS, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY BONE REGENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY BONE REGENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY BONE REGENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY SPINAL FUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY SPINAL FUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY SPINAL FUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY TISSUE ENGINEERING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY TISSUE ENGINEERING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY BONE TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY BONE TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY BONE TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY CARTILAGE TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY CARTILAGE TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY CARTILAGE TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY VASCULAR TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY VASCULAR TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY VASCULAR TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY DENTAL CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY DENTAL CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY DENTAL CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS BIOACTIVE GLASS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS BIOACTIVE GLASS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS BIOACTIVE GLASS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS BIOACTIVE GLASS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS BIOACTIVE GLASS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS BIOACTIVE GLASS MARKET SIZE, BY DENTISTRY, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS BIOACTIVE GLASS MARKET SIZE, BY ORTHOPEDICS, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS BIOACTIVE GLASS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS BIOACTIVE GLASS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA BIOACTIVE GLASS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA BIOACTIVE GLASS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA BIOACTIVE GLASS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA BIOACTIVE GLASS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA BIOACTIVE GLASS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA BIOACTIVE GLASS MARKET SIZE, BY DENTISTRY, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA BIOACTIVE GLASS MARKET SIZE, BY ORTHOPEDICS, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA BIOACTIVE GLASS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA BIOACTIVE GLASS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA BIOACTIVE GLASS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA BIOACTIVE GLASS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA BIOACTIVE GLASS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA BIOACTIVE GLASS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA BIOACTIVE GLASS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA BIOACTIVE GLASS MARKET SIZE, BY DENTISTRY, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA BIOACTIVE GLASS MARKET SIZE, BY ORTHOPEDICS, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA BIOACTIVE GLASS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA BIOACTIVE GLASS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA BIOACTIVE GLASS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA BIOACTIVE GLASS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA BIOACTIVE GLASS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA BIOACTIVE GLASS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA BIOACTIVE GLASS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA BIOACTIVE GLASS MARKET SIZE, BY DENTISTRY, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA BIOACTIVE GLASS MARKET SIZE, BY ORTHOPEDICS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA BIOACTIVE GLASS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA BIOACTIVE GLASS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE BIOACTIVE GLASS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE BIOACTIVE GLASS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE BIOACTIVE GLASS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE BIOACTIVE GLASS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE BIOACTIVE GLASS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE BIOACTIVE GLASS MARKET SIZE, BY DENTISTRY, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE BIOACTIVE GLASS MARKET SIZE, BY ORTHOPEDICS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE BIOACTIVE GLASS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE BIOACTIVE GLASS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST BIOACTIVE GLASS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST BIOACTIVE GLASS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST BIOACTIVE GLASS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST BIOACTIVE GLASS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST BIOACTIVE GLASS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST BIOACTIVE GLASS MARKET SIZE, BY DENTISTRY, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST BIOACTIVE GLASS MARKET SIZE, BY ORTHOPEDICS, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST BIOACTIVE GLASS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST BIOACTIVE GLASS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA BIOACTIVE GLASS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA BIOACTIVE GLASS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA BIOACTIVE GLASS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA BIOACTIVE GLASS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA BIOACTIVE GLASS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA BIOACTIVE GLASS MARKET SIZE, BY DENTISTRY, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA BIOACTIVE GLASS MARKET SIZE, BY ORTHOPEDICS, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA BIOACTIVE GLASS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA BIOACTIVE GLASS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC BIOACTIVE GLASS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC BIOACTIVE GLASS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC BIOACTIVE GLASS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC BIOACTIVE GLASS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC BIOACTIVE GLASS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC BIOACTIVE GLASS MARKET SIZE, BY DENTISTRY, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC BIOACTIVE GLASS MARKET SIZE, BY ORTHOPEDICS, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC BIOACTIVE GLASS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC BIOACTIVE GLASS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN BIOACTIVE GLASS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN BIOACTIVE GLASS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN BIOACTIVE GLASS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN BIOACTIVE GLASS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN BIOACTIVE GLASS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN BIOACTIVE GLASS MARKET SIZE, BY DENTISTRY, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN BIOACTIVE GLASS MARKET SIZE, BY ORTHOPEDICS, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN BIOACTIVE GLASS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN BIOACTIVE GLASS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. GCC BIOACTIVE GLASS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GCC BIOACTIVE GLASS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. GCC BIOACTIVE GLASS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 168. GCC BIOACTIVE GLASS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. GCC BIOACTIVE GLASS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. GCC BIOACTIVE GLASS MARKET SIZE, BY DENTISTRY, 2018-2032 (USD MILLION)
  • TABLE 171. GCC BIOACTIVE GLASS MARKET SIZE, BY ORTHOPEDICS, 2018-2032 (USD MILLION)
  • TABLE 172. GCC BIOACTIVE GLASS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 173. GCC BIOACTIVE GLASS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION BIOACTIVE GLASS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION BIOACTIVE GLASS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION BIOACTIVE GLASS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION BIOACTIVE GLASS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION BIOACTIVE GLASS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION BIOACTIVE GLASS MARKET SIZE, BY DENTISTRY, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION BIOACTIVE GLASS MARKET SIZE, BY ORTHOPEDICS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION BIOACTIVE GLASS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION BIOACTIVE GLASS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS BIOACTIVE GLASS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS BIOACTIVE GLASS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS BIOACTIVE GLASS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS BIOACTIVE GLASS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS BIOACTIVE GLASS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS BIOACTIVE GLASS MARKET SIZE, BY DENTISTRY, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS BIOACTIVE GLASS MARKET SIZE, BY ORTHOPEDICS, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS BIOACTIVE GLASS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS BIOACTIVE GLASS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. G7 BIOACTIVE GLASS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. G7 BIOACTIVE GLASS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. G7 BIOACTIVE GLASS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 195. G7 BIOACTIVE GLASS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. G7 BIOACTIVE GLASS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 197. G7 BIOACTIVE GLASS MARKET SIZE, BY DENTISTRY, 2018-2032 (USD MILLION)
  • TABLE 198. G7 BIOACTIVE GLASS MARKET SIZE, BY ORTHOPEDICS, 2018-2032 (USD MILLION)
  • TABLE 199. G7 BIOACTIVE GLASS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 200. G7 BIOACTIVE GLASS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. NATO BIOACTIVE GLASS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. NATO BIOACTIVE GLASS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. NATO BIOACTIVE GLASS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 204. NATO BIOACTIVE GLASS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. NATO BIOACTIVE GLASS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. NATO BIOACTIVE GLASS MARKET SIZE, BY DENTISTRY, 2018-2032 (USD MILLION)
  • TABLE 207. NATO BIOACTIVE GLASS MARKET SIZE, BY ORTHOPEDICS, 2018-2032 (USD MILLION)
  • TABLE 208. NATO BIOACTIVE GLASS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 209. NATO BIOACTIVE GLASS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL BIOACTIVE GLASS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES BIOACTIVE GLASS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES BIOACTIVE GLASS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES BIOACTIVE GLASS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES BIOACTIVE GLASS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES BIOACTIVE GLASS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES BIOACTIVE GLASS MARKET SIZE, BY DENTISTRY, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES BIOACTIVE GLASS MARKET SIZE, BY ORTHOPEDICS, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES BIOACTIVE GLASS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES BIOACTIVE GLASS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA BIOACTIVE GLASS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA BIOACTIVE GLASS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA BIOACTIVE GLASS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA BIOACTIVE GLASS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA BIOACTIVE GLASS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA BIOACTIVE GLASS MARKET SIZE, BY DENTISTRY, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA BIOACTIVE GLASS MARKET SIZE, BY ORTHOPEDICS, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA BIOACTIVE GLASS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA BIOACTIVE GLASS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)